Search company, investor...
TeDan Surgical Innovations company logo

TeDan Surgical Innovations

tedansurgical.com

Founded Year

2006

About TeDan Surgical Innovations

TeDan Surgical Innovations offers retraction and instrumentation for orthopedic, neuro, thoracic, and spine surgeries.

Headquarters Location

12615 W. Airort Blvd Suite #200

Sugar Land, Texas, 77478,

United States

877-726-0886

Missing: TeDan Surgical Innovations's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TeDan Surgical Innovations's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TeDan Surgical Innovations

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TeDan Surgical Innovations is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

TeDan Surgical Innovations Patents

TeDan Surgical Innovations has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/6/2017

7/31/2018

Surgical instruments, Surgical procedures and techniques, Threading (manufacturing), Geoplanidae, Surgery

Grant

Application Date

3/6/2017

Grant Date

7/31/2018

Title

Related Topics

Surgical instruments, Surgical procedures and techniques, Threading (manufacturing), Geoplanidae, Surgery

Status

Grant

Latest TeDan Surgical Innovations News

Gastric Cancer Diagnostic Procedure Market Size Forecasts at 6.5% CAGR during (2022-2028) - Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners

Mar 2, 2023

Global Gastric Cancer Diagnostic Procedure Market: Competitive Landscape and Key Developments Black Forest Medical Group, Integra LifeSciences Holdings Corp, Hill Rom Holding Inc, Eschmann Technologies Ltd, BD, TeDan Surgical Innovations, Barrfab Industria Commerce Import and Export of Hospital Equipment Ltda, Herbert Thailand Co Ltd, Medifa GmbH & Co KG, Micromar Industria e Com Ltda, and Schaerer Medical AG are a few of the key companies operating in the global gastric cancer diagnostic procedure market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. The product developments in the global gastric cancer diagnostic procedure market are mentioned below: In October 2021, Agilent Technologies Inc. received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx, which is meant to provide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. In August 2021, MiRXES launched GASTROClear is the world’s first RNA-powered blood test for the early detection of gastric cancer. The kit assesses the quantities of 12 microRNA biomarkers, allowing the company to detect as much as 87% of all gastric cancers. These include those at stage 0 of gastric cancer, also known as high-grade dysplasia. In August 2021, Myriad Genetics launched a new version of its MyRisk Hereditary Cancer Test. The test uses advanced technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with 8 hereditary cancer sites—breast, colon, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma cancers. Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00029842 Gastric cancer is a type of malignant cancer spread on the stomach's inner lining. Age, diet, and stomach diseases are among the major risk factors for gastric cancer. Symptoms of gastric cancer include indigestion, heartburn, bloating, and stomach discomfort or pain. The presence of a huge patient population with gastrointestinal tumors, lymphoma, and adenocarcinoma; an increase in the geriatric population; and a rise in alcohol consumption and smoking are among the other factors contributing to the gastric cancer prevalence, thereby contributing to the gastric cancer diagnostic procedure market. The US is currently leading the gastric cancer diagnostic procedure market, and the market growth in this country can be attributed to the growing prevalence of gastrointestinal diseases. For instance, the American Cancer Society estimated that ~26,500 new cases of gastric cancer (15,930 in men and 10,570 in women) would be diagnosed in 2023, and ~11,130 deaths (6,690 men and 4,440 women) would be due to gastric cancer. Further, the growing awareness of gastrointestinal diseases is likely to create growth opportunities for the market players in this country. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) is a nonprofit education and research organization that focuses on enhancing the quality of life for patients suffering from chronic digestive conditions. The 23rd Annual GERD Awareness Week was conducted from the 20th to the 26th in November 2022 with an aim to improve care by enhancing awareness and educating individuals. Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029842 Surging Cases of Helicobacter Pylori Infection Boosts Global Gastric Cancer Diagnostic Procedure Market Growth: Various studies in the past have established a relation between the colonization of the stomach with Helicobacter pylori (H. pylori), and the development of gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. According to a study “Current and Future Treatment of Helicobacter pylori Infections” in 2020, H. pylori is considered to be the most common human pathogens and was estimated to infect ~50% of the world's population. The infection usually develops during infancy but remains asymptomatic, while long-standing clinical symptoms such as gastritis, peptic ulcer disease, and stomach cancer may be evident in the later stages of life. According to the Journal of Drug Assessment, more than 50% of the world’s population is infected with H. pylori. The World Health Organization (WHO) states that developing countries have a ~90% prevalence rate of H. pylori, whereas developed countries record a lower rate, i.e., ~50%. Moreover, the rate significantly higher in adults than in children, i.e., 48.6% and 32.6%, respectively. Buy Premium Copy of Gastric Cancer Diagnostic Procedure Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00029842 Browse other research published by The Insight Partners: Global Gastric Balloon Market Size to 2027 - Global Analysis and Forecasts By Product (Single Gastric Balloons, Dual Gastric Balloons and Triple Gastric Balloons), Filling Material (Saline Filled and Gas Filled), End User (Bariatric Surgeons, Gastrointestinal Endoscopists, Nutritionists, Aesthetic Practitioners, and Other End Users), and Geography Global Gastric Buttons Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis by Offerings (Products and Accessories), Application (Children and Adults), Usage (Enteral Nutrition, Medications, Fluids, and Others), and End User (Hospitals, Clinics, and Others) Global Gastric Bands Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type (Adjustable Gastric Bands and Non-Adjustable Gastric Bands); End User (Hospitals , Ambulatory Surgical Centers, and Others) and Geography Global Gastric Antisecretory Drug Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (H2-receptor Antagonists, Gastric Proton Pump Inhibitors, Others); Application (Dyspepsia, Peptic Ulcer, Gastroesophageal Reflux, Others); End-user (Hospitals, Clinics, Others) and Geography Global Cancer Vaccines Market Size Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology (Dendritic Cells Cancer Vaccines, Recombinant Cancer Vaccines, Antigen Cancer Vaccines, Whole Cell Cancer Vaccines and Viral Vector Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer and Other Indications), End User (Pediatrics and Adults) and Geography Global Skin Cancer Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Melanoma, Non-melanoma); Type (Diagnosis , Therapeutics), and geography Global Precision Cancer Imaging Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Type (Bipolar EleMagnetic Resonance Imagingctrosurgical Devices, Nuclear Imaging, Ultrasound Imaging); End User (Hospitals, Diagnostic Centers, Research Centers, Others) Global Cancer Cachexia Market Size Forecast to 2028 - Covid-19 Impact and Global Analysis - By Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Others); Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers, Others); Distribution Channel (Hospital Stores, Retail Pharmacy Store, Online Pharmacy) and Geography Global Nanotechnology In Cancer Treatment Market Size Forecast to 2028 - COVID-19 Impact and Global Analysis By Application (Cancer Detection, Imaging, Drug Delivery, Radiotherapy, Immunotherapy, Phototherapy) Global Breast Cancer Screening Market Size Forecast to 2027 - COVID-19 Impact and Global Analysis by Test Type (Blood Marker tests, Imaging Test, Genetic Test, Immunohistochemistry Test); End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Geography About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi

TeDan Surgical Innovations Frequently Asked Questions (FAQ)

  • When was TeDan Surgical Innovations founded?

    TeDan Surgical Innovations was founded in 2006.

  • Where is TeDan Surgical Innovations's headquarters?

    TeDan Surgical Innovations's headquarters is located at 12615 W. Airort Blvd, Sugar Land.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.